Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases

被引:26
作者
Chen, Xianqiu [1 ]
Guo, Jian [2 ]
Yu, Dong [3 ]
Jie, Bing [3 ]
Zhou, Ying [1 ,4 ]
机构
[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Reprod Med, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Pulm Funct Test, Shanghai, Peoples R China
[3] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Radiol, Shanghai, Peoples R China
[4] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Clin Res Ctr, Shanghai, Peoples R China
基金
美国国家科学基金会;
关键词
progressive fibrosing interstitial lung disease; predictor of mortality; fibrotic changes; high-resolution computed tomography; pulmonary arterial hypertension; RESOLUTION COMPUTED-TOMOGRAPHY; IDIOPATHIC PULMONARY-FIBROSIS; FUNCTION INDEXES; PNEUMONIA; HYPERTENSION; PREVALENCE; DIAGNOSIS; SURVIVAL; CT;
D O I
10.3389/fphar.2021.754851
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Progressive fibrosing interstitial lung disease (PF-ILD) and idiopathic pulmonary fibrosis (IPF) share similar progression phenotype but with different pathophysiological mechanism. The purpose of this study was to assess clinical characteristics and outcomes of patients with PF-ILD in a single-center cohort.</p> Methods: Patients with PF-ILD treated in Shanghai Pulmonary Hospital from Jan. 2013 to Dec. 2014 were retrospectively analyzed. Baseline characteristics and clinical outcomes were collected for survival analysis to identifying clinical predictors of mortality.</p> Results: Among 608 patients with ILD, 132 patients met the diagnostic criteria for PF-ILD. In this single-center cohort, there were 51 (38.6%) cases with connective tissue disease-associated interstitial lung disease (CTD-ILD) and 45 (34.1%) with unclassifiable ILDs. During follow-up, 83 patients (62.9%) either died (N = 79, 59.8%) or underwent lung transplantations (N = 4, 3.0%) with a median duration follow-up time of 53.7 months. Kaplan-Meier survival curves revealed that the 1, 3 and 5-years survival of PF-ILD were 90.9, 58.8 and 48.1%, respectively. In addition, the prognosis of patients with PF-ILD was similar to those with IPF, while it was worse than non-PF-ILD ones. Multivariate Cox regression analysis demonstrated that high-resolution computed tomography (HRCT) scores (HR 1.684, 95% CI 1.017-2.788, p = 0.043) and systolic pulmonary artery pressure (SPAP) > 36.5 mmHg (HR 3.619, 95%CI 1.170-11.194, p = 0.026) were independent risk factors for the mortality of PF-ILD.</p> Conclusion: Extent of fibrotic changes on HRCT and pulmonary hypertension were predictors of mortality in patients with PF-ILD.</p>
引用
收藏
页数:9
相关论文
共 39 条
[1]   Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases [J].
Adegunsoye, Ayodeji ;
Oldham, Justin M. ;
Bellam, Shashi K. ;
Montner, Steven ;
Churpek, Matthew M. ;
Noth, Imre ;
Vij, Rekha ;
Strek, Mary E. ;
Chung, Jonathan H. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2019, 16 (05) :580-588
[2]  
Brown Kevin K, 2020, Eur Respir J, V55, DOI 10.1183/13993003.00085-2020
[3]   Biomarkers in systemic sclerosis [J].
Castro, Susan V. ;
Jimenez, Sergio A. .
BIOMARKERS IN MEDICINE, 2010, 4 (01) :133-147
[4]   Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study [J].
De Sadeleer, Laurens J. ;
Hermans, Frederik ;
De Dycker, Els ;
Yserbyt, Jonas ;
Verschakelen, Johny A. ;
Verbeken, Eric K. ;
Verleden, Geert M. ;
Wuyts, Wim A. .
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (01)
[5]   Lung Manifestations in the Rheumatic Diseases [J].
Doyle, Tracy J. ;
Dellaripa, Paul F. .
CHEST, 2017, 152 (06) :1283-1295
[6]   Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality [J].
Edey, Anthony J. ;
Devaraj, Anand A. ;
Barker, Robert P. ;
Nicholson, Andrew G. ;
Wells, Athol U. ;
Hansell, David M. .
EUROPEAN RADIOLOGY, 2011, 21 (08) :1586-1593
[7]   Nintedanib in Progressive Fibrosing Interstitial Lung Diseases [J].
Flaherty, K. R. ;
Wells, A. U. ;
Cottin, V ;
Devaraj, A. ;
Walsh, S. L. F. ;
Inoue, Y. ;
Richeldi, L. ;
Kolb, M. ;
Tetzlaff, K. ;
Stowasser, S. ;
Coeck, C. ;
Clerisme-Beaty, E. ;
Rosenstock, B. ;
Quaresma, M. ;
Haeufel, T. ;
Goeldner, R-G ;
Schlenker-Herceg, R. ;
Brown, K. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1718-1727
[8]   Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis [J].
Giacomelli, Roberto ;
Afeltra, Antonella ;
Alunno, Alessia ;
Bartoloni-Bocci, Elena ;
Berardicurti, Onorina ;
Bombardieri, Michele ;
Bortoluzzi, Alessandra ;
Caporali, Roberto ;
Caso, Francesco ;
Cervera, Ricard ;
Chimenti, Maria Sole ;
Cipriani, Paola ;
Coloma, Emmanuel ;
Conti, Fabrizio ;
D'Angelo, Salvatore ;
De Vita, Salvatore ;
Di Bartolomeo, Salvatore ;
Distler, Oliver ;
Doria, Andrea ;
Feist, Eugen ;
Fisher, Benjamin A. ;
Gerosa, Maria ;
Gilio, Michele ;
Guggino, Giuliana ;
Liakouli, Vasiliki ;
Margiotta, Domenico Paolo Emanuele ;
Meroni, Pierluigi ;
Moroncini, Gianluca ;
Perosa, Federico ;
Prete, Marcella ;
Priori, Roberta ;
Rebuffi, Chiara ;
Ruscitti, Piero ;
Scarpa, Raffaele ;
Shoenfeld, Yehuda ;
Todoerti, Monica ;
Ursini, Francesco ;
Valesini, Guido ;
Vettori, Serena ;
Vitali, Claudio ;
Tzioufas, Athanasios G. .
AUTOIMMUNITY REVIEWS, 2019, 18 (01) :93-106
[9]   Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis [J].
Gimenez, Andrea ;
Storrer, Karin ;
Kuranishi, Lilian ;
Soares, Maria Raquel ;
Ferreira, Rimarcs Gomes ;
Pereira, Carlos A. C. .
THORAX, 2018, 73 (04) :391-392
[10]   Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression [J].
Guler, Sabina A. ;
Winstone, Tiffany A. ;
Murphy, Darra ;
Hague, Cameron ;
Soon, Jeanette ;
Sulaiman, Nada ;
Li, Kathy H. ;
Dunne, James ;
Wilcox, Pearce G. ;
Ryerson, Christopher J. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (12) :1427-1433